chufangao/CTO huggingface dataset:
Clinical trial NCT03278808: Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
Official title: A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum in a Controlled Human Malaria Infection (CHMI) Model
Sponsor: U.S. Army Medical Research and Development Command (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The IND has been withdrawn from FDA
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-17
Primary completion date: 2019-12-30
Completion date: 2020-01-01
Plan to share individual participant data: NO
Clinical trial NCT05719012: Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
Official title: Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19: a Randomized, Double-blind, Parallel-controlled Study
Sponsor: Shanghai East Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Difficulty in Recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-01
Primary completion date: 2023-12-01
Completion date: 2024-03-30
Plan to share individual participant data: NO
Clinical trial NCT05431543: Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Official title: A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Sponsor: LENZ Therapeutics, Inc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 59.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-06
Primary completion date: 2022-12-14
Completion date: 2022-12-14
Plan to share individual participant data: NO
Clinical trial NCT03575572: Colchicine in Postoperative Fontan Patients
Official title: Colchicine in Postoperative Fontan Patients (CPFP)
Acronym: CPFP
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Staffing changes impacted by COVID-19 pandemic resulting in inadequate personnel to facilitate study.
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-29
Primary completion date: 2021-01-13
Completion date: 2021-01-13
Plan to share individual participant data: NO
Clinical trial NCT04397718: Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization
Official title: Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix
Acronym: HITCH
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 96.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-06
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Plan to share individual participant data: NO
Clinical trial NCT05631327: A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Official title: Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors
Sponsor: Jazz Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated based on a business decision by the Sponsor.
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-19
Primary completion date: 2024-04-24
Completion date: 2024-04-24
Clinical trial NCT03189030: Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer
Official title: A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer
Sponsor: Aduro Biotech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated due to business realignment
Enrollment: 28.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-02
Primary completion date: 2019-10-15
Completion date: 2020-09-02
Clinical trial NCT04601883: Colchicine as Treatment for People With Hand Osteoarthritis
Official title: Colchicine Treatment for Patients With Hand Osteoarthritis: A Randomised, Placebo-controlled Trial.
Acronym: COLOR
Sponsor: Frederiksberg University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-15
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03749616: Effect of NSAID Use on Pain and Opioid Consumption Following Distal Radius Fracture
Official title: Effect of NSAID Use on Pain and Opioid Consumption Following Distal Radius Fracture: A Prospective, Randomized Study
Acronym: Adult NSAID
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Original principal investigator left the institution and investigator replacing him did not have the patient population to enroll as needed.
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-02
Primary completion date: 2022-03-24
Completion date: 2022-03-24
Clinical trial NCT04252287: A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
Official title: Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
Acronym: CHIEF-HF
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 476.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-10
Primary completion date: 2021-11-09
Completion date: 2021-11-09
Baseline population: Safety analysis set included all randomized participants who received at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT05887479: The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity
Official title: The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity
Sponsor: Sisli Hamidiye Etfal Training and Research Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: insufficient number of patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-25
Primary completion date: 2023-07-15
Completion date: 2023-08-15
Clinical trial NCT03810690: Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
Official title: A Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
Sponsor: ModernaTX, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study was terminated before the start of dosing due to a business decision and not due to safety or efficacy reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-05-28
Primary completion date: 2020-08-18
Completion date: 2020-08-18
Plan to share individual participant data: NO
Clinical trial NCT04132388: Hidradenitis Suppurativa Patient Experience With Humira Treatment
Official title: Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Sponsor and site agreed the research would not happen now; several delays and other issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-20
Primary completion date: 2022-09-07
Completion date: 2022-09-07
Plan to share individual participant data: NO
Clinical trial NCT02135419: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Official title: ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Acronym: ANCHOR
Sponsor: AIDS Malignancy Consortium (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 4446.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-09-24
Primary completion date: 2021-08-06
Completion date: 2024-03-31
Baseline population: Participants who were randomized and received assigned intervention
Plan to share individual participant data: YES
IPD sharing description: A CDISC-mapped, de-identified version of the study data with appropriate documentation (data dictionary, annotated static copies of electronic case report forms, clinical protocol, informed consent document) of the data elements will be made available via a public data repository: the AIDS Malignancy Consortium (AMC) Data Commons.
IPD time frame: IPD will only be shared with external investigators following conclusion of all participant data collection and the acceptance of a manuscript(s) that addresses all trial objectives, via release of the data to a public data repository, anticipated to occur on or after August 2025. Data will be available according to the archival terms of the AMC Data Commons.
IPD access criteria: Qualified researchers with plans approved by the AMC Executive Committee who have entered into a Data Use Agreement (DUA) with the AMC will be granted data access. Research plans may include, but are not limited to, research on HIV/AIDS, anal HSIL screening and/or treatment, HPV-associated malignancies, anal cancer, and associated conditions.
Clinical trial NCT04369547: Roflumilast TMS-EEG Plasticity
Official title: A Double-blind Placebo-controlled Crossover Study of Roflumilast Synaptic Plasticity Enhancement: a TMS-EEG Study
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Resource limitations
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-09-01
Completion date: 2023-09-01
Plan to share individual participant data: NO
IPD sharing description: There will be no sharing of individual participant data.
Clinical trial NCT04374253: A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
Official title: An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Enrollment: 1382.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-26
Primary completion date: 2023-03-06
Completion date: 2023-03-06
Baseline population: ITT analysis set included all enrolled participants, who received at least one dose of study drug. Participants were analyzed by the treatment they were randomized to in the parent studies (GRADUATE I or GRADUATE II).
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04374019: Novel Agents for Treatment of High-risk COVID-19 Positive Patients
Official title: Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow accrual,
Enrollment: 13.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-05-01
Primary completion date: 2020-12-21
Completion date: 2022-01-12
Limitations and caveats: Thsi study was closed to accrual due to slow accrual rate. No conclusions on efficacy can be made due to a lack of statistical power in each arm.
Plan to share individual participant data: NO
Clinical trial NCT03785691: Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
Official title: Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial
Acronym: VOMIT
Sponsor: Nordsjaellands Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recruiting difficulties
Enrollment: 58.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-03-01
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: YES
IPD sharing description: Access to patient level data and supporting clinical documents may be requested. Requests will be reviewed on the basis of methodological proposal. Patient data will be de-identified to protect the privacy of trial patients in line with applicable laws and regulations.
IPD time frame: Following publication, no end date.
Clinical trial NCT03320642: GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Official title: GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated by sponsor
Enrollment: 84.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-27
Primary completion date: 2021-02-25
Completion date: 2022-02-17
Plan to share individual participant data: NO
Clinical trial NCT05769959: Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Official title: An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision (not related to safety, efficacy or quality).
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-06-15
Primary completion date: 2024-03-19
Completion date: 2024-03-19
Plan to share individual participant data: NO
Clinical trial NCT04371952: DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19)
Official title: Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study
Acronym: DYNAMIC
Sponsor: Nantes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: withdrawal due to the evolution of the epidemic, the arrival of vaccination and because the associated centres could no longer commit to the number of inclusions requested
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-01
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Plan to share individual participant data: NO
Clinical trial NCT04311177: Losartan for Patients With COVID-19 Not Requiring Hospitalization
Official title: Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 117.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-09
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Plan to share individual participant data: NO
Clinical trial NCT03953261: Effect of Curcumin on Systemic Lupus Erythematosus
Official title: Effect of Curcumin on Systemic Lupus Erythematosus
Sponsor: Loma Linda University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID and lack of support staff 2. lack of support staff to conduct the study
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2022-04-13
Completion date: 2022-04-13
Plan to share individual participant data: NO
Clinical trial NCT03168464: Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Official title: Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-09
Primary completion date: 2022-03-11
Completion date: 2022-03-11
Limitations and caveats: The study was terminated early leading to small numbers of subjects analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04402008: Study of Poziotinib in Japanese Patients With NSCLC
Official title: A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Spectrum Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business decision, not related to safety.
Enrollment: 42.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-23
Primary completion date: 2023-02-15
Completion date: 2023-02-15
Baseline population: Safety population included all participants who signed informed consent, enrolled and received at least 1 dose of poziotinib.
Limitations and caveats: The study was prematurely terminated for business reasons and not related to safety.
Plan to share individual participant data: NO
Clinical trial NCT03710044: Investigation of Flare and Remission in Subjects With Atopic Dermatitis
Official title: Investigation of Flare and Remission in Atopic Dermatitis in an Integrated Longitudinal Trial: Effects of Systemic Treatment With Cyclosporine A
Sponsor: LEO Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Strategic decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-31
Primary completion date: 2020-08-31
Completion date: 2020-08-31
Plan to share individual participant data: NO
Clinical trial NCT03770299: An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
Official title: A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention With Adjuvant Nivolumab in Non-Small Cell Lung Cancer Participants With ctDNA-detected Minimal Residual Disease After Surgical Resection
Acronym: CheckMate 9TN
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business objectives have changed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-15
Primary completion date: 2023-03-14
Completion date: 2024-03-14
Plan to share individual participant data: YES
IPD sharing description: Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html
Clinical trial NCT04466917: A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Official title: A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision to early terminate the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-15
Primary completion date: 2022-11-13
Completion date: 2022-11-13
Plan to share individual participant data: NO
Clinical trial NCT03302585: High-Dose Vitamin D Induction in Optic Neuritis
Official title: A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2)
Acronym: VitaDON2
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: inability to meet recruitment goals
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-23
Primary completion date: 2024-05-09
Completion date: 2024-05-09
Plan to share individual participant data: NO
Clinical trial NCT02825719: Ulipristal Use in Chinese Population
Official title: Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population
Sponsor: Queen Mary Hospital, Hong Kong (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Ulipristal was withdrawal from the market
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-02
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
IPD sharing description: This is to protect the privacy of individual patients
Clinical trial NCT04223661: Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Official title: Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035)
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-06
Primary completion date: 2022-12-31
Completion date: 2023-12-31
Clinical trial NCT04753164: Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Official title: Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 136.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-16
Primary completion date: 2022-03-21
Completion date: 2022-03-25
Baseline population: Randomized population
Plan to share individual participant data: NO
Clinical trial NCT04047563: Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
Official title: A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke
Sponsor: Pharmazz, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 158.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-10
Primary completion date: 2022-02-10
Completion date: 2022-02-10
Plan to share individual participant data: NO
IPD sharing description: Results will be communicated and published as manuscript